Insider Purchases Worth US$1.27m See Losses As MiMedx Group Market Value Drops To US$566m
MiMedx Group insiders, including CEO Joseph Capper, purchased US$1.27 million worth of shares at an average price of US$6.34 in the last year. However, a recent 10% price decline has reduced the value of these investments to US$762,000. Despite the current losses, the purchases suggest insiders believe in the company's future value, and they collectively own 1.9% of the company.
MiMedx Group, Inc. (MDXG) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of MiMedx Group, Inc. (MDXG), a biotechnology company specializing in placental tissue allografts. It details the company's stock performance, including current trading prices, historical data, and analyst insights. The page also features financial highlights, recent news, and comparison tools with similar companies in the biotechnology sector.
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
MIMEDX will sponsor and participate in two major advanced wound care conferences: the Symposium on Advanced Wound Care (SAWC) Spring 2026 and MedStar Georgetown University Hospital’s Diabetic Limb Salvage (DLS) Conference. The company will showcase its latest research and expanded portfolio of wound care solutions through scientific presentations, clinician education, and exhibits. This participation underscores MIMEDX's commitment to advancing wound care science and supporting clinicians with evidence-based treatment options for complex wounds.
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
MIMEDX Group, Inc. announced its sponsorship and participation in two major wound care conferences: the Symposium on Advanced Wound Care (SAWC) Spring 2026 and MedStar Georgetown University Hospital’s Diabetic Limb Salvage (DLS) Conference. The company will showcase its expanded portfolio and present new scientific data, emphasizing its commitment to advancing wound care solutions through clinical evidence and clinician education. MIMEDX aims to support healthcare professionals in managing complex wounds and improving patient outcomes.
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
MIMEDX Group (NASDAQ: MDXG) announced its sponsorship and participation in two major wound care conferences: SAWC Spring 2026 and the Diabetic Limb Salvage (DLS) 2026 Conference. The company will present scientific data through symposia, poster, and oral presentations, showcasing its peptide-based and placental allograft wound care technologies. This engagement highlights MIMEDX's commitment to advancing wound care science, particularly with its stock trading near its 52-week low.
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
MIMEDX Group, Inc. announced its sponsorship and participation in two major advanced wound care conferences: SAWC Spring 2026 and MedStar Georgetown University Hospital’s Diabetic Limb Salvage (DLS) Conference. The company will showcase its advanced wound care technologies and present new scientific data, including oral abstracts and poster presentations, focusing on improving patient outcomes and limb preservation strategies. MIMEDX aims to highlight its clinical evidence and expanding portfolio of solutions designed to support clinicians in managing complex wounds through education and real-world application.
MiMedx Group Inc (MDXG) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for MiMedx Group Inc (MDXG). It is presented within the context of online trading with the Capital.com investment app.
MiMedx Group Inc (MDXG) Stock Price Quote Today & Current Price Chart | Capital.com Australia
This page provides current trading information and key statistics for MiMedx Group Inc (MDXG) stock as a CFD, noting its availability for CFD trading on Capital.com Australia. It details trading conditions such as spreads, overnight funding adjustments, and margin requirements. The article also includes a section on recent share-related news covering other companies like NVIDIA, Tesla, Siemens Energy, and BYD, and features customer reviews for Capital.com.
MIMEDX Announces Launch of CHORIOFIX™
MiMedx Group, Inc. (MIMEDX) has launched CHORIOFIX™, an advanced placental allograft wound care product. This new product is designed with a unique two-chorion layer structure for enhanced handling and is being evaluated in the CAMPAIGN trial against standard of care for diabetic foot ulcers. CHORIOFIX™ further expands MIMEDX's diverse portfolio of healing solutions.
MIMEDX Announces Launch of CHORIOFIX™
MIMEDX has launched CHORIOFIX™, an advanced placental allograft product designed for wound care. This new product features two chorion layers, making it a thicker option for treating complex and deep wounds. The company has also added CHORIOFIX™ to its CAMPAIGN trial to evaluate its effectiveness against standard care for non-healing diabetic foot ulcers.
MiMedx adds its thickest graft yet for deep, hard-to-treat wounds
MiMedx (Nasdaq: MDXG) announced the commercial launch of CHORIOFIX, a lyophilized placental allograft designed as the company's thickest product to date for acute and chronic wound care. CHORIOFIX, composed of two chorion layers with an intact intermediate layer, aims to improve handling, positioning, and suturing. It has also been added to the ongoing CAMPAIGN trial to evaluate its performance against standard of care for non-healing diabetic foot ulcers.
MIMEDX Announces Launch of CHORIOFIX™
MIMEDX announced the commercial launch of CHORIOFIX™, a new advanced wound care product made from placental allografts. This product, designed with a thick, dual-sided chorion configuration, aims to improve handling and is suitable for challenging deep and tunneling wounds. MIMEDX is also evaluating CHORIOFIX™ in its CAMPAIGN trial to assess its performance against standard care for diabetic foot ulcers.
MIMEDX Announces Launch of CHORIOFIX™
MIMEDX has launched CHORIOFIX™, an advanced placental allograft product designed for advanced wound care. This new therapy, stemming from MIMEDX's understanding of the chorion layer, is structurally enhanced for better handling and is thicker than previous products. CHORIOFIX has also been added to the CAMPAIGN trial to evaluate its performance against the standard of care for non-healing diabetic foot ulcers.
MiMedx Group Inc stock faces scrutiny amid recent 8.9% pullback in biotech sector volatility
MiMedx Group Inc (US60251E1029) recently experienced an 8.9% stock price decline on NASDAQ, reflecting broader biotech sector volatility. Despite this pullback, market observers believe the company's long-term prospects in advanced wound care solutions remain strong, presenting a potential buying opportunity for DACH investors. The article details MiMedx's core business, financial health, growth drivers, and risks, highlighting its unique position in regenerative medicine.
MiMedx Group, Inc (NASDAQ:MDXG) Given Consensus Recommendation of "Moderate Buy" by Analysts
MiMedx Group, Inc (NASDAQ:MDXG) has received a consensus "Moderate Buy" rating from analysts, with an average one-year price target of $9.60. Despite some recent price target reductions by certain brokers, the company recently surpassed quarterly earnings and revenue estimates. MiMedx is a biopharmaceutical firm focused on regenerative biomaterial products derived from human placental tissues for wound healing and surgical applications.
MiMedx (NASDAQ: MDXG) CCO has 6,762 shares withheld for tax
MiMedx's Chief Commercial Officer, Kimberly Maersk-Moller, had 6,762 shares of common stock withheld by the company on March 13, 2026, to cover tax obligations related to restricted stock vesting. This transaction, executed at $4.38 per share, was a routine tax-related disposition and not an open-market sale. Following this withholding, Maersk-Moller directly owns 329,450 shares of MiMedx common stock.
MIMEDX (MDXG) counsel has 20,245 shares withheld to cover tax on vested stock
MIMEDX GROUP, INC.'s General Counsel, William Frank Hulse IV, reported a tax-related share disposition where 20,245 common stock shares were withheld to cover tax obligations from vested restricted stock. This is categorized as a routine compensation and tax event, not an open-market trade. Following the transaction, Hulse IV directly holds 543,195 shares.
First Light Asset Management LLC Buys 1,725,458 Shares of MiMedx Group, Inc $MDXG
First Light Asset Management LLC significantly increased its stake in MiMedx Group, Inc. (MDXG) by 89.5% in the third quarter, purchasing an additional 1,725,458 shares. This makes MiMedx Group its 17th-largest position, with a total holding valued at approximately $25.5 million. Despite beating recent earnings estimates, the stock is trading near its 12-month low, and analysts have a "Moderate Buy" consensus rating with an average target price of $9.60.
MiMedx (NASDAQ: MDXG) GC gains PSU shares, withholds some for taxes
MiMedx Group's General Counsel and CAO, William Frank Hulse IV, received common shares through the vesting of performance stock units (PSUs) at $4.50 per share. A portion of these shares was withheld to cover tax obligations, in line with company policy. After these transactions, Hulse directly owns 563,440 shares of MIMEDX common stock.
MiMedx (MDXG) CCO receives shares from PSU vesting, with tax withholding
MiMedx's Chief Commercial Officer, Kimberly Maersk-Moller, received 42,845 shares of common stock on March 10, 2026, due to the vesting of performance stock units (PSUs) granted on March 13, 2023. These PSUs covered a performance period from January 1, 2023, to December 31, 2025. Of the acquired shares, 21,270 were withheld to cover tax obligations, leaving her with a direct ownership of 336,212 shares of common stock.
Healing wounds with insights: How MiMedx powers innovation in healthcare with Strategy solutions
MiMedx, a leader in regenerative medicine, uses Strategy's data analytics and AI solutions to drive innovation in wound care, burns, and surgical applications. By leveraging a robust BI platform with a semantic layer, MiMedx has consolidated data, enhanced security, and enabled advanced analytics, including GenAI bots and HyperIntelligence. This partnership has allowed MiMedx to achieve operational excellence, streamline decision-making, and improve reporting, ultimately supporting its mission of helping humans heal.
MiMedx (NASDAQ: MDXG) CFO updates stake after PSU vesting
MiMedx Group CFO Doug Rice reported recent equity compensation activity related to performance stock units (PSUs). He acquired 243,000 shares of common stock upon vesting of PSUs covering the 2023-2025 performance period. Following these transactions, including the disposition of 96,363 shares to cover tax obligations as per company policy, Mr. Rice directly holds 412,315 shares of MiMedx common stock.
Trigran Investments Inc. Sells 689,430 Shares of MiMedx Group, Inc $MDXG
Trigran Investments Inc. recently decreased its stake in MiMedx Group, Inc. by 8.2% in the third quarter, selling 689,430 shares, though it still holds over 5% of the company. MiMedx Group has shown strong financial performance, beating recent quarterly earnings estimates with $0.14 EPS on $118.1 million in revenue. The company maintains a "Moderate Buy" analyst rating and a consensus price target of $9.60.
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
MIMEDX has launched AMNIOFIX Thyroid Shields, a new product designed for endocrine surgery. These allografts, derived from dehydrated human amnion/chorion membrane, are intended to provide a protective barrier to the Recurrent Laryngeal Nerve and parathyroid glands following thyroidectomy, aiming to reduce the incidence of RLN damage. The product's effectiveness is supported by a retrospective study showing a 76% reduction in RLN damage post-op.
Thyroid surgery shield shows 76% drop in vocal nerve damage in study
MiMedx (Nasdaq: MDXG) has launched AMNIOFIX Thyroid Shields, a new product designed for endocrine surgery to protect the recurrent laryngeal nerve (RLN) and parathyroid glands after thyroidectomy. A retrospective study highlighted a significant 76% reduction in 24-hour RLN damage with the use of these shields. This expansion strengthens MiMedx's surgical product portfolio, aiming to enhance patient safety and operating room efficiency.
MiMedx Group (NASDAQ:MDXG) Sets New 1-Year Low - What's Next?
MiMedx Group (NASDAQ:MDXG) recently hit a new 52-week low of $4.70, prompting questions about its future. Despite the stock downturn, the company surpassed quarterly earnings estimates with $0.14 EPS on $118.1M revenue, maintaining a "Moderate Buy" consensus rating from analysts with an average price target of $9.60. MiMedx exhibits strong financial health with a 4.32 current ratio and 0.06 debt-to-equity ratio, alongside significant institutional ownership.
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
MIMEDX has launched AMNIOFIX® Thyroid Shields, an expansion of its AMNIOFIX product line for endocrine surgery. These allografts create a protective barrier for the Recurrent Laryngeal Nerve (RLN) and parathyroid glands after thyroidectomy, aiming to support healing and prevent damage. A study showed a 76% reduction in RLN damage incidence using AMNIOFIX, highlighting its potential to improve surgical outcomes.
Analysts Issue Forecasts for MiMedx Group Q1 Earnings
Northland Securities has provided Q1 2026 earnings per share (EPS) estimates for MiMedx Group (NASDAQ:MDXG), projecting ($0.03) with a full-year consensus of $0.30 per share. The company recently surpassed expectations in its previous earnings report, recording $0.14 EPS against a $0.09 consensus and achieving $118.1 million in revenue. Analysts generally maintain a "Moderate Buy" rating with an average price target of $9.60, despite the stock currently trading around $4.89.
MiMedx Group (MDXG) Delivers Record Full Year Revenue
MiMedx Group, Inc. (MDXG) reported record quarterly and full-year revenue and profitability for fiscal 2025, driven by strong growth in its wound care and surgical segments. The company exceeded Street targets for Q4 revenue and EPS, with improved gross profit margins. MiMedx anticipates fiscal 2026 revenue to be between $340 million and $360 million.
MiMedx Group (MDXG) Delivers Record Full Year Revenue
MiMedx Group, Inc. (NASDAQ: MDXG) achieved record quarterly and full-year revenue and profitability, driven by double-digit growth in its wound care and surgical segments. The company reported Q4 revenue of $118.1 million, exceeding targets, and projected fiscal 2026 revenue between $340 million and $360 million. MiMedx specializes in advanced placental tissue allografts for various medical applications.
MiMedx Group (MDXG) Revenue Jump To US$118.1 Million Tests Slow Growth Narrative
MiMedx Group (MDXG) reported strong Q4 2025 revenue of US$118.1 million and a basic EPS of US$0.10, contributing to a trailing twelve-month revenue of US$418.6 million and EPS of US$0.33. While the company maintains an 11.6% net profit margin, its projected revenue growth of 3.8% is slower than the broader US market, raising concerns among critics despite a P/E ratio below the industry average. The article discusses both bullish and bearish perspectives on MDXG's future potential, focusing on product expansion, operational efficiencies, and potential risks like reimbursement changes.
MiMedx Group (NASDAQ:MDXG) Stock Price Down 8.8% - Here's What Happened
Shares of MiMedx Group (NASDAQ:MDXG) fell 8.8% on Thursday after the company released its Q4 and full-year results, which, despite beating EPS and revenue expectations, included 2026 revenue guidance below consensus. The guidance miss, suggesting potential deceleration due to reimbursement changes and slower adoption, overshadowed the positive Q4 performance, record adjusted EBITDA, and a new $100M share repurchase program. The stock experienced a significant drop in trading volume, indicating investor concerns about near-term growth.
MiMedx Group Q4 Earnings Call Highlights
MiMedx Group reported record 2025 results with $419 million in net sales and nearly $106 million in adjusted EBITDA, driven by strong growth in both wound care and surgical segments. The company anticipates a near-term revenue pullback in Q1 2026 due to Medicare reimbursement changes in the wound-care market, guiding 2026 revenue to $340-$360 million. MiMedx is expanding its surgical portfolio and clinical evidence, including new product launches and a distribution agreement for a PRP system, while remaining disciplined in M&A with a share repurchase program in place.
MiMedx (MDXG) details wound-care expansion, new products and Medicare shifts
MiMedx Group, Inc. (MDXG) has detailed its expansion in wound care and surgical biologics, driven by placental allografts and a growing portfolio of animal-derived and distributed products. The company announced significant Medicare reimbursement reforms for skin substitutes effective in 2026, shifting to a flat rate per square centimeter, which could affect industry economics. MiMedx reported strong financial results for 2025, with net sales reaching $418.6 million, an increase of 20% over 2024, despite anticipated headwinds from the new Medicare reimbursement policies.
Record 2025 growth and $100M buyback at MiMedx (NASDAQ: MDXG)
MiMedx Group, Inc. reported record fourth-quarter and full-year 2025 financial results, with net sales reaching $118.1 million for Q4 (up 27% year-over-year) and $418.6 million for the full year (up 20%). The company also announced a board-authorized share repurchase program of up to $100 million over two years, signaling confidence in its financial health. While forecasting lower net sales for 2026 ($340-360 million) due to anticipated Medicare reimbursement changes, MiMedx expects long-term annual net sales growth in the low double-digits and Adjusted EBITDA margins above 20%.
MIMEDX Group Inc (NASDAQ:MDXG) Stock Dips Despite Strong Earnings Beat
MIMEDX Group Inc (NASDAQ:MDXG) reported strong fourth-quarter and full fiscal year 2025 earnings, significantly beating Wall Street expectations with record sales and EPS. Despite this financial outperformance, the stock experienced a puzzling dip of approximately 3.6% in after-hours trading. This reaction may be due to profit-taking, valuation concerns, or scrutiny of future guidance, as analysts project continued but more moderated growth for 2026.
Earnings Flash (MDXG) MiMedx Group, Inc. Posts Q4 Adjusted EPS $0.14 per Share, vs. FactSet Est of $0.09
MiMedx Group, Inc. (MDXG) announced a Q4 adjusted EPS of $0.14 per share, significantly exceeding the FactSet estimate of $0.09. The company also reported Q4 revenue of $118.1 million, surpassing the FactSet estimate of $106.8 million. MiMedx specializes in placental biologics, developing and distributing tissue allografts for wound care and surgical applications.
MiMedx: Q4 Earnings Snapshot
MiMedx Group Inc. (MDXG) reported fourth-quarter earnings of $15.2 million, or 10 cents per share, with adjusted earnings of 14 cents per share. The biomaterials developer posted $118.1 million in revenue for the quarter and $418.6 million for the full year, with a profit of $48.6 million. MiMedx anticipates full-year revenue to be between $340 million and $360 million.
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
MIMEDX announced record operating and financial results for the fourth quarter and full year 2025, with net sales growing 27% year-over-year in Q4 and 20% for the full year. The company reported GAAP net income of $15 million in Q4 and Adjusted EBITDA of $29 million. MIMEDX also projected 2026 net sales between $340-360 million and authorized a $100 million share repurchase program, despite anticipated short-term disruptions from Medicare reimbursement changes.
This MiMedx Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Several Wall Street analysts initiated coverage on various companies, providing bullish outlooks. Citizens analyst David Turkaly started coverage on MiMedx Group Inc. (NASDAQ: MDXG) with a Market Outperform rating and a $10 price target. Notable initiations also included York Space Systems Inc. (NYSE: YSS) by Baird and Raymond James, Ethos Technologies (NASDAQ: LIFE) by Goldman Sachs, and PicS N.V. (NASDAQ: PICS) by RBC Capital.
Citizens initiates MiMedx stock with outperform on reimbursement outlook By Investing.com
Citizens initiated coverage on MiMedx Group Inc. (NASDAQ:MDXG) with a Market Outperform rating and a $10.00 price target. The firm believes the company, which manufactures biologics and skin substitutes for chronic wounds, is set for recovery following recent reimbursement headwinds, citing CMS’s new industry-wide price cap solution for 2026 and beyond. Despite trading near its 52-week low, MiMedx remains profitable, and recent developments like a new distribution agreement and research findings on its placental allografts are expected to support its growth.
MiMedx (NASDAQ: MDXG) COO reports 61,961-share tax withholding on vesting
MiMedx Group's Chief Operating Officer, Ricci S. Whitlow, reported a tax-related disposition of 61,961 shares of common stock. These shares were withheld by the company at $5.12 per share to cover tax withholding requirements upon the vesting of restricted stock. Following this transaction, Whitlow directly owns 388,662 shares of MiMedx Group common stock, including shares acquired through the Employee Stock Purchase Plan.
MiMedx Group (MDXG) Projected to Post Quarterly Earnings on Wednesday
MiMedx Group (MDXG) is scheduled to release its Q4 2025 earnings before market open on Wednesday, February 25th, with analysts forecasting earnings of $0.09 per share. The stock currently trades at $5.16, with a market cap of $764.2 million, and holds a "Moderate Buy" consensus rating among analysts, despite recent price target reductions. Institutional investors significant ownership of the company's shares.
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MIMEDX Group, Inc. (Nasdaq: MDXG) announced it will report its fourth quarter and full year 2025 operating and financial results after market close on February 25, 2026. The company's senior management team will host a webcast and conference call at 4:30 p.m. ET on the same day to discuss the results. A replay of the webcast will be available on the company's website for approximately 30 days.
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MiMedx Group, Inc. (Nasdaq: MDXG) announced it will host a conference call on February 25, 2026, to discuss its operating and financial results for the fourth quarter and full year ended December 31, 2025. The results will be released after market close, and the call will follow at 4:30 p.m. Eastern Time. Investors can access the webcast or dial in to the conference call to review the company's performance.
MiMedx Group, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
MiMedx Group, Inc. will release its fourth quarter and full-year 2025 financial results on February 25, 2026, after market close, followed by a conference call and webcast at 4:30 p.m. ET. The company, which specializes in healing solutions for chronic wounds, aims to provide transparency and insights into its performance for investors. The announcement also includes details on insider trading activity, revenue figures, hedge fund movements, and analyst ratings for MDXG.
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MIMEDX Group, Inc. has announced it will report its Q4 and full-year 2025 operating and financial results on Wednesday, February 25, 2026, after the market closes. The company's senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to review the results. MIMEDX is a leader in healing solutions, providing products for wound care, burn, and surgical sectors.
Northland Securities Comments on MiMedx Group Q1 Earnings
Northland Securities has revised its Q1 2026 EPS estimate for MiMedx Group (NASDAQ:MDXG) down to $0.00 from $0.02, while forecasting Q3 and Q4 EPS of $0.04 and $0.05, respectively. The company currently holds a "Moderate Buy" consensus rating with an average target price of $10.67, significantly above its current trading price of $5.03. MiMedx Group, a biopharmaceutical company specializing in regenerative biomaterial products, is characterized by a market cap of approximately $745 million and high institutional ownership.
MiMedx Strengthens Surgical Portfolio with Key Distribution Agreement
MiMedx Group, Inc. has entered into an exclusive distribution partnership with Summit Products Group for three FDA 510(k) cleared surgical wound care products: Hydrelix, NovaForm, and G4Derm Plus. This strategic move aims to expand MiMedx's commercial reach and reduce reliance on single product segments, especially in response to new U.S. healthcare regulations from CMS effective January 1. The company's fourth-quarter and full-year 2025 financial results, due February 25, are anticipated to reveal the impact of this new strategy.
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
MIMEDX Group, Inc. has announced an exclusive distribution agreement with Summit Products Group for three new 510(k) cleared products: Hydrelix, NovaForm, and G4Derm Plus. These products, which include collagen matrix, bioglass and collagen-based wound dressing, and flowable peptide matrix, are designed to enhance MIMEDX's Surgical & Wound product portfolio. The partnership aims to strengthen MIMEDX's offering in the evolving surgical and wound care markets.
